Partner Interview
Published February 13, 2025
Lonza, WuXi Biologics & CDMO Global Market: Competitive Landscape Evolution
inpractise.com/articles/lonza-wuxi-biologics-and-cdmo-global-market-competitive-landscape-evolution
Executive Bio
Executive at AGC Biologics
Interview Transcript
Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.
This is a snippet of the transcript.to get full access.
Do you see any particular drug category having a larger shift from China to other countries?
The major reason why it's enough to look at WuXi is that this company is a main driver and one of the most established CDMOs in China, with FDA approval, EMA approval, and high-quality standards. Therefore, a lot of Western customers ended up at WuXi for slightly cheaper prices, more flexible conditions, and ultimately good quality and timely deliveries. WuXi was a high-quality player offering very reasonable terms and conditions, attracting many Western customers who now need to look for new homes.
Free Sample of 50+ Interviews
Sign up to test our content quality with a free sample of 50+ interviews.
Or contact sales for full access
Related Content

AGC Biologics & Western vs Chinese CDMOs
Executive at AGC Biologics

Sartorius: Upstream Bioprocessing Market Dominance
Former Senior Product Management Director at Sartorius Stedim Biotech

Kneat: Life Sciences Validation Software Implementation
Former CQV Engineer at VEQTOR

Bio-Rad Laboratories: Competitive Differentiators
Former VP at Bio-Rad Laboratories
© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.